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ABSTRACT 27 
Background and Aims 28 
Prebiotic inulin-type fructans are widely consumed in the diet and may have contrasting 29 
effects in Crohn’s disease by stimulating gut microbiota and/or by generating functional 30 
gastrointestinal symptoms. The aim of this study was to measure fructan and oligofructose 31 
intakes in patients with active and inactive Crohn’s disease compared with healthy controls. 32 
Methods 33 
Patients with active Crohn’s disease (n=98), inactive Crohn’s (n=99) and healthy controls 34 
(n=106) were recruited to a case-control study. Dietary intake of inulin-type fructans was 35 
measured using a specific food frequency questionnaire and was compared between the three 36 
groups and between patients with different disease phenotypes (Montreal classification). 37 
Associations between intakes and disease activity (Harvey Bradshaw Index, HBI) were also 38 
undertaken.   39 
Results 40 
Patients with active Crohn’s disease had lower fructan intakes (median 2.9 g/d, IQR 1.8) than 41 
those with inactive Crohn’s (3.6 g/d, 2.1, P=0.036) or controls (3.9 g/d, 2.1, P=0.003) and 42 
lower oligofructose intakes (2.8 g/d, 1.8) than inactive Crohn’s (3.5 g/d, 2.2, P=0.048) or 43 
controls (3.8 g/d, 2.1, P=0.003). There were no differences in intakes related to disease site or 44 
behaviour. There were negative correlations between HBI wellbeing score and fructan intake 45 
(ρ=-0.154, P=0.03) and oligofructose intake (ρ=-0.156, P=0.028) and for the HBI abdominal 46 
pain score and fructan (ρ=-0.164, P=0.021) and oligofructose intake (ρ=-0.157, P=0.027).  47 
Conclusions 48 
Patients with active Crohn’s disease consume lower quantities of fructans and oligofructose 49 
than their inactive counterparts and healthy controls. The impact of lower intakes of prebiotic 50 
fructans on gut microbiota are unknown and warrant further research. 51 
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 52 
Keywords: inflammatory bowel disease, inulin, fructan, oligofructose, fructans, FODMAPs  53 
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INTRODUCTION 55 
The aetiology of Crohn’s disease includes an inappropriate immune response towards 56 
commensal microbiota in genetically susceptible individuals. Many studies utilising in-depth 57 
molecular microbiological techniques have consistently demonstrated that the luminal and 58 
mucosal microbiota in Crohn’s disease are characterised by reduced diversity and lower 59 
levels of Firmicutes such as Roseburia and Faecalibacterium prausnitzii.1-3 These bacteria 60 
ferment dietary substrates, including non-digestible or non-absorbed carbohydrates, to 61 
produce short-chain fatty acids such as butyrate,4 which has been shown to promote 62 
immunoregulation.5 A range of interventions that target the modification of the 63 
gastrointestinal microbiota have therefore been investigated in Crohn’s disease including 64 
antibiotics, probiotics and prebiotics. 65 
 66 
Prebiotics selectively stimulate the growth and/or activity of one or a limited number of 67 
microbial genera/species in the gut microbiota that confer(s) health benefits to the host.6 The 68 
most widely investigated prebiotics are the inulin-type fructans, and many studies have 69 
shown that dietary supplementation stimulates the numbers of bifidobacteria6 and some 70 
studies also report stimulation of F. prausnitzii7 and the production of short-chain fatty 71 
acids.4,6 These findings are important to Crohn’s disease since such changes in the luminal 72 
and mucosal environment might therefore elicit immunological and therapeutic benefit, for 73 
example the evidence of higher levels of F. prausnitzii in those with extended remission.8 74 
 75 
Inulin-type fructans consist of D‐fructose monomers linked by β2→1 bonds to form linear 76 
polymers, some with a terminal glucose molecule. Inulin-type fructans refer to all molecules 77 
ranging in length from 2-60 degrees of polymerisation, whilst oligofructose refers only to 78 
shorter molecules of 2-10 degrees of polymerisation.6 Inulin-type fructans are widely 79 
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consumed in the diet, the majority being present as oligofructose in cereals such as wheat and 80 
rye and in vegetables such as onions, leeks, and asparagus, although longer polymers (i.e. 11-81 
60 degrees of polymerisation) are also contained within chicory root and artichokes.9-11  82 
 83 
Despite the potential mechanisms for inulin-type fructans to benefit Crohn’s disease through 84 
modification of the gastrointestinal microbiota, supplementation studies have failed to result 85 
in the induction of remission of active disease.12,13 Some patients with Crohn’s disease also 86 
experience functional gastrointestinal symptoms (e.g. abdominal pain, bloating, diarrhoea) 87 
that are not the result of active disease, and a significant minority also fulfil criteria for the 88 
functional bowel disorder irritable bowel syndrome.14 Fermentable carbohydrates such as 89 
inulin-type fructans have been implicated in the generation of gastrointestinal symptoms in 90 
some people with functional bowel disorders.15,16 This presents a conundrum whereby 91 
prebiotic carbohydrates that might beneficially modify the gastrointestinal microbiota and be 92 
fermented to produce short-chain fatty acids, may in some also induce functional 93 
gastrointestinal symptoms.  94 
 95 
Diet and nutrition play an important role in the management of Crohn’s disease and have 96 
been identified as issues of primary concern in patients.17 Many patients believe that diet can 97 
induce or exacerbate symptoms17 and self-imposed diet restrictions have been reported, 98 
including of foods rich in inulin-type fructans.18-20 To our knowledge there are no large 99 
studies investigating dietary intakes of inulin-type fructans in Crohn’s disease. The aim of 100 
this case-control study was to measure intakes of inulin-type fructans and oligofructose in 101 
patients with both active and inactive Crohn’s disease compared with healthy controls. 102 
103 
Page 5 of 31
https://mc.manuscriptcentral.com/ecco-jcc
Manuscripts submitted to Journal of Crohn's and Colitis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
6 
 
 
 
METHODS 104 
This was a case-control study using interviewer-administered questionnaires to measure 105 
intakes of inulin-type fructans from habitual diet in patients with active Crohn’s disease, 106 
inactive Crohn’s disease and healthy controls. This study was conducted according to the 107 
guidelines laid down in the Declaration of Helsinki and all procedures involving patients and 108 
healthy controls were approved by the National Research Ethics Service (South East 109 
Research Ethics Committee, Bromley Local Research Ethics Committee). Written informed 110 
consent was obtained from all participants prior to study enrolment. 111 
 112 
Participants 113 
Patients with Crohn’s disease were recruited from four inflammatory bowel disease 114 
outpatient clinics across London, United Kingdom (UK). Patients were eligible if they had a 115 
documented diagnosis of Crohn’s disease for at least three months, supported by radiological 116 
or histological reports and were aged between 18-65 years. Exclusion criteria included a 117 
recent change in medication (e.g. change in immunosuppressant or biologic therapy within 12 118 
weeks, oral 5-aminosalicyclic acid or steroids within 4 weeks, use of rectal preparations 119 
during the preceding 2 weeks). Patients completed questio naires prior to any changes in 120 
medication at that appointment to ensure that the measurement of disease activity was 121 
reflective of their recent disease activity and coincident to the period of survey of inulin-type 122 
fructan intake. Further exclusion criteria included pure perianal Crohn’s disease, other 123 
gastrointestinal disorders (e.g. short bowel syndrome, previous pan-proctocolectomy / 124 
significant colonic resection), other severe major organ disorders (e.g. hepatic, renal, 125 
endocrine, respiratory, neurological, or cardiovascular disease or previous diagnosis of cancer 126 
with disease-free state ≤ 2 years) or self-reported pregnancy or lactation, all of which may 127 
otherwise impact on dietary intake. 128 
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 129 
Patients were categorised as having active disease if they had a Harvey Bradshaw Index 130 
(HBI) of ≥4 together with a C-reactive protein >10 mg/dL and were categorised as having 131 
inactive disease if they had an HBI of ≤3 and a C-reactive protein <10 mg/dL. The combined 132 
use of clinical and serum inflammatory markers was used to increase the sensitivity and 133 
specificity of the active and inactive definitions. Patients not fulfilling both criteria were not 134 
recruited. 135 
 136 
Healthy adults (18-65 y) were recruited as controls through a circular email sent to all 137 
students and staff at King’s College London and through the snowballing technique, in order 138 
to recruit subjects from outside of the institution. Exclusion criteria included having Crohn’s 139 
disease or any other gastrointestinal disorder (e.g. ulcerative colitis, irritable bowel syndrome, 140 
chronic constipation, diarrhoea), previous gastrointestinal surgery or other severe major organ 141 
disorder as above, including those likely to impact dietary intake (e.g. diabetes, 142 
cardiovascular disease) or self-reported pregnancy or lactation. 143 
 144 
Data collection 145 
Basic demographic data including sex, age, smoking status and ethnicity were collected at the 146 
time of recruitment. For patients with Crohn’s disease, a range of clinical information was 147 
also recorded. A gastroenterologist recorded each patient’s disease activity using the HBI to 148 
score general wellbeing, stool frequency, pain, abdominal mass and extra-intestinal 149 
manifestations.21,22 The gastroenterologist also recorded the Crohn’s disease phenotype using 150 
the Montreal classification to record age at diagnosis, disease location and disease 151 
behaviour.23 152 
 153 
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Intakes of inulin-type fructans (hereon referred to as fructans) and oligofructose were 154 
measured using a specific food frequency questionnaire (FFQ).11 The FFQ comprised 23 155 
foods and drinks (eight fruits and vegetables; 15 composite foods e.g. breads, breakfast 156 
cereals, pastry products etc) that make contributions to fructan and oligofructose intakes in 157 
the UK diet. The FFQ has been shown to be a valid and reliable method for measuring 158 
fructan and oligofructose intakes for use in dietary surveys.11 Patients with Crohn’s disease 159 
and healthy controls were asked to recall the frequency and portion size of consumption of 160 
the 23 items over the preceding week. 161 
 162 
The FFQ was administered by the researcher using standardised questioning procedures in 163 
order to minimise administrator bias. Flash cards were available if participants were 164 
unfamiliar with some food items (e.g. asparagus, globe artichoke, Jerusalem artichoke, 165 
chicory root). Data from the FFQ’s were subsequently checked by a dietitian and entered into 166 
a bespoke food composition database. Dietary intake of fructans and oligofructose from food 167 
commodities (e.g. onion, asparagus etc) was calculated using food composition data.9 Dietary 168 
intake from composite foods was assessed by first calculating the food commodity content 169 
(e.g. total wheat, total rye) of each composite food on the FFQ (e.g. breads, pastry products) 170 
using the Food Commodity Intake Database (US Department of Agriculture and the US 171 
Environmental Protection Agency, United States) and then calculating the fructan and 172 
oligofructose content of these food commodities. Values for small, medium and large portion 173 
sizes were taken from standard food portion values in the UK.24  174 
 175 
Statistical Analysis 176 
Statistical analyses were performed using SPSS software package version 20 (IBM SPSS 177 
Software, NY, US). Categorical data were compared between groups using the chi-square test 178 
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or the Fisher’s Exact test (where more than 25% of cells had counts less than 5). Parametric 179 
continuous data (e.g. demographic data) was compared between the groups using an unpaired 180 
t-test or one-way analysis of variance (ANOVA), as appropriate. Fructan and oligofructose 181 
intakes were tested for equality of variances using Levene’s test and for normality using and 182 
Kolomogorov-Smirnov and Shapiro-Wilk tests. Where necessary data was transformed to 183 
achieve a satisfactory residual plot. Fructan and oligofructose intakes were found to be not 184 
normally distributed and therefore were compared between two groups using a Mann 185 
Whitney test and between three groups using a Kruskal Wallis test and Bonferroni post hoc 186 
correction.  Fructan and oligofructose intake data was also divided into tertiles, which were 187 
compared between groups using the chi-square test. Relationships between fructan and 188 
oligofructose intakes and HBI score(s) were analysed using Spearman’s rho. The results of all 189 
tests were considered significant if P≤0.05. Categorical data is reported as n (%) and 190 
continuous data as mean (SD) and/or median (IQR) as appropriate.   191 
192 
Page 9 of 31
https://mc.manuscriptcentral.com/ecco-jcc
Manuscripts submitted to Journal of Crohn's and Colitis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
10 
 
 
 
RESULTS 193 
A total of 303 participants were recruited (98 active Crohn’s disease, 99 inactive Crohn’s 194 
disease, 106 healthy controls). There were no significant differences between the groups in 195 
key demographic data including age, sex or ethnicity (Table 1). Although not statistically 196 
significant, more patients with active Crohn’s disease were current smokers (28.6%) than 197 
those with inactive disease (17.2%) or healthy controls (19.8%) (P=0.127), perhaps reflecting 198 
the impact of smoking on exacerbation of Crohn’s disease.25 Patients in the active group had 199 
mild/moderately active Crohn’s disease (HBI median 9, min 4 – max 19) and those in the 200 
inactive group had only mildly elevated disease (HBI median 1, min 0 – max 3).    201 
 202 
There were significant differences in intakes of total fructans (p<0.001) and oligofructose 203 
(p=0.001) between groups (Table 2). Following post hoc corrections, patients with active 204 
Crohn’s disease were shown to have lower fructan intakes (median 2.9 g/d, IQR 1.8) than 205 
both those with inactive Crohn’s disease (3.6 g/d, 2.1, P=0.036) or healthy controls (3.9 g/d, 206 
2.1, P=0.003) and lower oligofructose intakes (median 2.8 g/d, IQR 1.8) than those with 207 
inactive  Crohn’s disease (3.5 g/d, 2.2, P=0.048) or healthy controls (3.8 g/d, 2.1, P=0.003). 208 
There were no significant differences in intakes of total fructans or oligofructose between the 209 
inactive Crohn’s disease group and healthy controls. When all 303 participants were divided 210 
into tertiles of intake, the highest tertile of fructan intake (≥ 4.19 g/d) consisted of fewer 211 
patients with active Crohn’s disease (21.4%) than those with inactive Crohn’s (35.4%) and 212 
healthy controls (42.5%) (P=0.006), with the same pattern for tertiles of oligofructose intake 213 
(Table 2).  214 
     215 
In all participants, the majority of total fructans and oligofructose came from wheat, onion, 216 
banana and garlic, with a range of other commodities contributing very small amounts 217 
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(‘other’ e.g. leeks, rye, artichoke). There were significant differences in the contribution of 218 
the major food commodities to intakes of total fructans and oligofructose between groups 219 
(Table 3). Following post hoc corrections, patients with active Crohn’s disease consumed a 220 
greater proportion of total fructans from wheat (median 69.6%, IQR 40.6%) than both those 221 
with inactive Crohn’s disease (62.8%, 37.5%, P=0.039) or healthy controls (57.9%, 34.4%, 222 
P=0.003) and a greater proportion of oligofructose from wheat (median 70.5%, IQR 39.8) 223 
than those with inactive Crohn’s disease (64.6%, 34.6%, P=0.042) or healthy controls 224 
(60.9%, 32.0%, P=0.006).  Furthermore, those with active Crohn’s disease consumed a lower 225 
proportion of total fructans (median 12.8%, IQR 25.3%) and oligofructose (13.4%, 25.7%,) 226 
from onion than patients with inactive Crohn’s disease (fructan 20.1%, 22.4 P=0.042; 227 
oligofructose 20.9%, 22.4 P=0.033). Healthy controls consumed considerably more fructans 228 
and oligofructose form other sources (e.g. leeks, rye, artichoke) than patients with Crohn’s 229 
disease, irrespective of whether disease was active or not (Table 3).     230 
 231 
In terms of Montreal disease classification, neither disease site nor disease behaviour had a 232 
significant effect on intakes of total fructans or oligofructose, either when data was analysed 233 
for the combined Crohn’s disease population or when active and inactive groups were 234 
analysed separately (Table 4). 235 
 236 
There was a significant, though small, negative correlation between patients’ HBI wellbeing 237 
score and both total fructan intake (ρ= -0.154, P=0.03) and oligofructose intake (ρ= -0.156, 238 
P=0.028) and for the HBI abdominal pain score and total fructan (ρ= -0.164, P=0.021) and 239 
oligofructose intake (ρ= -0.157, P=0.027) (Table 5). As the scores for these increased, 240 
indicating poorer wellbeing and more severe abdominal pain, total fructan and oligofructose 241 
intakes decreased. When analysed within patient groups, there was only a significant 242 
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correlation between higher abdominal pain score and intakes of total fructans (ρ= -0.216, 243 
P=0.032) and oligofructose (ρ= -0.208, P=0.040) in patients with active Crohn’s disease. 244 
There were no significant associations between intakes of total fructans and oligofructose and 245 
any of the other components of the HBI. 246 
247 
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DISCUSSION 248 
This is the first study to report intakes of fructans and oligofructose in a large sample of 249 
patients with Crohn’s disease, and therefore to our knowledge there are no data with which to 250 
directly compare our findings. We identified lower intakes of total fructans and oligofructose 251 
in patients with active disease compared to those with inactive disease and healthy controls, 252 
despite no differences between patients with inactive Crohn’s disease and healthy controls. 253 
There were small but significant associations between lower intakes of fructans and 254 
oligofructose and both impaired wellbeing and more severe abdominal pain, especially in 255 
those with active disease. 256 
 257 
The lower intakes of fructans and oligofructose in active Crohn’s disease could be the result 258 
of a variety of factors, including the result of specific diets to induce remission, the restriction 259 
of foods or food components to reduce gastrointestinal symptoms or impaired overall dietary 260 
intake. 261 
 262 
Firstly, patients with active Crohn’s disease could be following specific diets to induce 263 
remission. Elimination diets such as the low fat, fibre limited, exclusion (LOFFLEX) diet are 264 
sometimes used during active disease to assist in induction of remission,26 although in the 265 
current study nobody reported to be following a specific elimination diet. A systematic 266 
review of randomised controlled trials recently reported little evidence of benefit of fibre 267 
restriction or fibre supplementation for inducing remission in Crohn’s disease.27 Secondly, 268 
patients with Crohn’s disease sometimes restrict fibre intake in order to reduce 269 
gastrointestinal symptoms, with dietary fibre exclusion the most common form of dietary 270 
advice provided by gastroenterologists to patients with inflammatory bowel disease in the 271 
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UK.28 Consequently, some studies report lower fibre intakes in active Crohn’s disease 272 
compared with inactive disease.29  273 
 274 
However, it is important to highlight that reducing fibre intake does not necessarily equate to 275 
reducing fructan intake. For example, the major dietary source of fructan is wheat, and 276 
switching from wholemeal bread to refined white bread will reduce fibre intake but would 277 
have little impact on fructan intake.30 Therefore, the lower fructan intake in active Crohn’s 278 
disease reported here is unlikely to be merely the result of patients reducing their fibre intake 279 
to induce disease remission or to reduce gastrointestinal symptoms.  280 
 281 
Thirdly, gastrointestinal symptoms (e.g. abdominal pain, bloating) may be triggered by other 282 
foods or food components and patients with active Crohn’s disease may reduce their intake of 283 
these to avoid such symptoms.17 For example, one study found that 19% of patients with 284 
Crohn’s disease reported wheat triggered gastrointestinal symptoms,17 whilst another found 285 
that gastrointestinal symptoms were induced by a range of fructan-containing food items, 286 
including breakfast cereals (15.2%), breads (18.2%), cakes and biscuits (22.6%) and 287 
vegetables (19.6%).18 A randomised controlled trial in active Crohn’s disease reported greater 288 
abdominal pain, flatulence and borborygmi during fructan/oligofructose supplementation, 289 
albeit in doses of up to 15 g/d.12 However, in the current study those with more severe 290 
abdominal pain (higher HBI abdominal pain score) actually had lower intakes of fructan. 291 
Rather than suggesting low intakes result in pain it is likely that patients with more severe 292 
pain choose to avoid consumption of foods that exacerbate symptoms, such as fructan-293 
containing foods. In the current study, patients with active Crohn’s disease consumed lower 294 
proportions of fructan and oligofructose from onion and other vegetables (e.g. leeks, 295 
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asparagus, artichokes). This perhaps may be the result of a move towards consumption of less 296 
diverse diets and the adoption of more basic dietary intake. 297 
 298 
Functional gastrointestinal symptoms including abdominal pain, flatulence and diarrhoea are 299 
common in Crohn’s disease, with up to 44% of patients with active disease and 35% of 300 
patients with inactive disease also fulfilling criteria for the functional bowel disorder irritable 301 
bowel syndrome.14 Indeed a retrospective uncontrolled study found that restriction of a range 302 
of short-chain fermentable carbohydrates (fermentable oligo-, di- and monosaccharides and 303 
polyols, termed FODMAPs) resulted in a significant reduction of abdominal pain (50% of 304 
patients), flatulence (56%) and diarrhoea (46%) in patients with Crohn’s disease, with 305 
ongoing dietary restriction of fructans being a significant factor associated with reduction in 306 
gastrointestinal symptoms.31 The current study only measured intakes of fructans, and did not 307 
measure intakes of other FODMAPs (e.g. α-galacto-oligosaccharides, polyols etc) that are 308 
relevant to gastrointestinal symptom generation, and such studies are now warranted. 309 
 310 
Surprisingly we showed no association between liquid stools and fructan intake. However, 311 
the HBI is a validated measure of disease activity rather than a specific measure of stool 312 
output and it records liquid stools, rather than liquid/loose stools or the subjective symptom 313 
of diarrhoea.21,22 We also failed to show that disease location or disease behaviour had a 314 
significant effect on fructan intake. Other studies have also shown no difference across 315 
Crohn’s disease types in the intake of micronutrients32 or in the prevalence of fructose 316 
malabsorption.33   317 
 318 
Our study showed no difference in intakes of fructans and oligofructose between patients 319 
with inactive Crohn’s disease and healthy controls. Indeed a number of studies,29,34 though 320 
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not all,35 fail to find any differences in total energy intake (as a marker of global food intake) 321 
between inactive Crohn’s disease and healthy controls. The lack of difference in fructan 322 
intakes between inactive disease and the healthy controls is unlikely due to poor estimates of 323 
intake in the latter (e.g. due to sampling bias) as intakes in our healthy control population 324 
(fructans 3.9 g/d, oligofructose 3.8 g/d) were similar to that previously reported in the UK 325 
(fructans 4.0 g/d, oligofructose 3.8 g/d).11  326 
 327 
Clinical consequences and clinical application  328 
The consequence of lower intakes of fructans and oligofructose in active Crohn’s disease is 329 
unclear. On one hand it may be viewed as an attempt by patients to select foods that do not 330 
trigger gastrointestinal symptoms, whereas alternatively there may be concern that lower 331 
intakes may negatively impact the gastrointestinal microbiota. Numerous studies indicate that 332 
fructans stimulate the numbers of bifidobacteria and some studies also report stimulation of 333 
Faecalibacterium prausnitzii.6,7 These microbiological findings are important since higher 334 
bifidobacteria have been associated with greater IL-10 positive dendritic cells and higher F. 335 
prausnitzii are associated with lower IL-6 positive dendritic cells.36 In addition, patients with 336 
higher F. prausnitzii are more likely to have extended remission.8 The differences in 337 
gastrointestinal microbiota between active and inactive Crohn’s disease has been extensively 338 
investigated,1-3 but the potential modifying effect of differences in dietary intake on this 339 
association (including that of fructan and oligofructose) has not been explored and is now 340 
warranted. 341 
 342 
Recent guidelines for the dietetic management of patients with Crohn’s disease have 343 
recommended that exclusion diet be considered in maintenance of Crohn’s disease, and that 344 
restriction of short-chain fermentable carbohydrates may potentially be useful in those who 345 
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experience functional gastrointestinal symptoms.37 However, only a minority of patients with 346 
inflammatory bowel disease are given tailored dietary advice by a gastroenterologist or 347 
dietitian17,28 and therefore patients with IBD may seek alternative and potentially less 348 
evidence-based alternatives.26 This may lead to the unnecessary avoidance of foods that 349 
contribute important nutritional and non-nutritional components to the diet.   350 
 351 
Strengths and limitations 352 
The data presented here are from a large cohort of patients with active and inactive Crohn’s 353 
disease and a large healthy control group with similar demographic characteristics. The use of 354 
prebiotic supplements containing fructans and/or oligofructose is generally low in this patient 355 
group38 and none of the patients in the current study were using such supplements and 356 
therefore the fructan intakes reported here constitute the total amounts consumed. However, 357 
we did not measure body weight, body mass index or total dietary intake, and therefore the 358 
findings may reflect lower intake of all foods, rather than just those containing fructans and 359 
oligofructose specifically. However the evidence for reduction in global food intake during 360 
active Crohn’s disease is equivocal.  361 
 362 
The FFQ used in this study has been validated in a healthy population, but not in patients 363 
with Crohn’s disease. Whilst our cohort were similar in gender and age to those in the 364 
validation study, dietary assessment tools should be validated in the population in which they 365 
are to be used. It was also developed using the standard food composition data available at 366 
the time9 which did not include subsequent data for the fructan and oligofructose content of a 367 
wider range of foods including various other vegetables40 and cereals.41 We may therefore 368 
have underestimated fructan and oligofructose intakes, although this would have occurred 369 
consistently across all three groups, unless these additional foods are differentially consumed 370 
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between active and inactive disease and health. Finally, the FFQ measured short-term intake 371 
only. We therefore cannot comment on longer term intakes of fructans and oligofructose and 372 
do not attempt to make any associations with the pathogenesis of disease activity. Further 373 
research on whole diet intake in Crohn’s disease that includes analysis of intakes of a range 374 
of carbohydrates is required in order to explore the relationship between diet, disease activity 375 
and gastrointestinal symptoms further. 376 
 377 
CONCLUSION 378 
Patients with active Crohn’s disease consume lower amounts of fructans and oligofructose 379 
than their inactive counterparts and healthy controls. This is particularly the case for those 380 
with poorer well-being and more severe abdominal pain. Vegetable such as onion, leeks and 381 
artichokes etc contributed lower proportions to fructan and oligofructose intakes in patients 382 
with active Crohn’s disease. The lower intakes of fructan and oligofructose may be the result 383 
of specific diets to induce remission, the restriction of foods or food components to reduce 384 
gastrointestinal symptoms or impaired dietary intake. The impact of the lower intakes of 385 
these prebiotic compounds in active Crohn’s disease are unknown and warrant further 386 
research. 387 
 388 
389 
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Table 1 Participant demographic and clinical data 532 
 Active Crohn’s 
(n= 98) 
Inactive Crohn’s 
(n=99) 
Healthy controls 
(n=106) 
P value 
Age, y, mean (SD) 38. 5  (12.8) 36.2  (11.2) 36.6  (8.5) 0.283* 
Females, n (%) 61  (62.2) 54  (54.5) 64  (60.4) 0.516† 
Current smoker, n (%) 28  (28.6) 17  (17.2) 21  (19.8) 0.127† 
Ethnicity, n (%)       0.651† 
    White 67  (68.4) 74  (74.7) 76  (71.7)  
    Asian 22  (22.4) 15  (15.2) 23  (21.7)  
    Black 5  (5.1) 8  (8.1) 5  (4.7)  
    Mixed/other 4  (4.1) 2  (2.0) 2  (1.9)  
Harvey Bradshaw Index, median (IQR) 9 (4) 1 (2) - - <0.001‡ 
Montreal Classification        
Disease duration, y, mean (SD) 10.5   (7.6) 14.0  (10.6) - - 0.008§ 
Disease Location, n (%)       0.061† 
    L1 Ileal 13  (13.3) 26  (26.3) - -  
    L2 Colon 22  (22.4) 22  (22.2) - -  
    L3 Ileocolonic 63  (64.3) 51  (51.5) - -  
    L4 Disease site modifier 4 (4.1) 6  (6.1) - - 0.747ǁ 
Disease Behaviour, n (%)     - - 0.454† 
    B1 Non-stricturing/penetrating 50 (51) 57  (57.6) - -  
    B2 Stricturing 29 (29.6) 29  (29.3) - -  
    B3 Penetrating 19 (19.4) 13  (13.1) - -  
    P Perianal disease modifier 20 (20.4) 22  (22.2) - - 0.862ǁ 
*
 P values are the result of an ANOVA 533 
†
 P values are the result of a chi-squared test 534 
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‡ P values are the result of a Mann Whitney test 535 
§ P values are the result of an unpaired t-test 536 
ǁ P values are the result of a Fisher’s exact test 537 
538 
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Table 2 Total fructan and oligofructose intakes (g/d) and tertiles of intake among 539 
patients with Crohn’s disease and healthy controls 540 
 Active 
Crohn’s 
(n=98) 
Inactive Crohn’s 
(n=99) 
Healthy controls 
(n=106) 
P value 
Total fructans        
Daily intakes, g/d, median (IQR) 2.9  (1.8)a 3.6  (2.1)b 3.9  (2.1)b <0.001* 
Tertiles of fructan intake, n (%)       0.006† 
    Low (≤ 2.77 g/d) 45  (45.9) 30  (30.3) 26  (24.5)  
    Medium (2.78 - 4.18 g/d) 32  (32.7) 34  (34.3) 35  (33.0)  
    High (≥ 4.19 g/d) 21  (21.4) 35  (35.4) 45  (42.5)  
Oligofructose        
Daily intakes, g/d, median (IQR) 2.8  (1.8)a 3.5  (2.2)b 3.8  (2.1)b 0.001* 
Tertiles of oligofructose intake, n (%)       0.018† 
    Low (≤ 2.69 g/d) 44  (44.9) 30  (30.3) 27  (25.5)  
    Medium (2.70 – 4.05 g/d) 32  (32.7) 34  (34.3) 35  (33.0)  
    High (≥ 4.06 g/d) 22  (22.4) 35  (35.4) 44  (41.5)  
Values within a row with unlike superscript letters were significantly different following a 541 
Mann Whitney test and Bonferroni post hoc correction. 542 
*
 P values are the result of a Kruskal Wallis test  543 
†
 P values are the result of a chi-squared test 544 
545 
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Table 3 Percentage contribution of food commodities to intakes of total fructans and 546 
oligofructose among patients with Crohn’s disease and healthy controls 547 
Percentage contribution 
to intakes, median (IQR) 
Active Crohn’s 
(n=98) 
Inactive Crohn’s 
(n=99) 
Healthy controls 
(n=106) 
P 
value* 
Total fructans 
       
 Wheat 69.6  (40.6)a 62.8  (37.5)b 57.9  (34.3)b 0.003 
 Onion 12.8  (25.3)a 20.1  (22.4)b 17.4  (23.6)a,b 0.048 
 Banana 0.0  (5.8)a 2.2  (7.3)a 2.8  (8.0)b 0.033 
 Garlic 0.9  (2.1)a 1.8  (4.1)b 0.9  (3.3)a,b 0.001 
 Other† 0.02  (6.3)a 0.03  (9.6)a 7.4  (27.0)b <0.001 
Oligofructose        
 Wheat 70.5  (39.8)a 64.6  (34.6)b 60.9  (32.0)b 0.005 
 Onion 13.4  (25.7)a 20.9  (22.4)b 17.6  (23.6)a,b 0.036 
 Banana 0.0  (6.2)a 2.2  (7.3)a 3.1  (8.5)b 0.026 
 Garlic 0.4  (0.8)a 0.7  (1.9)b 0.4  (1.4)a,b 0.001 
 Other† 0.02  (5.5)a 0.03  (6.8)a 5.3  (22.5)b <0.001 
Values within a row with unlike superscript letters were significantly different following a 548 
Mann Whitney test and Bonferroni post hoc correction. 549 
*
 P values are the result of a Kruskal Wallis test  550 
†
 “Other” represents the combined percentage contribution from leeks, asparagus, barley, 551 
globe artichoke, jerusalem artichoke, rye and dandelion; each of which contributed  <1% of 552 
total fructan and oligofructose OF intake for >80% participants. 553 
554 
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Table 4 Total fructan and oligofructose intakes of patients with Crohn’s disease 555 
comparing different Montreal disease classifications 556 
Disease Site Ileal Colonic Ileocolonic P value* 
Total fructan intakes, g/d, median (IQR)        
 All Crohn’s disease (n=39, 44, 114) 3.4  (2.1) 3.3  (2.1) 3.1  (2.3) 0.265 
 Active Crohn’s (n=13, 22, 63) 2.8  (2.4) 2.7  (1.6) 3.0  (1.9) 0.942 
 Inactive Crohn’s (n=26, 22, 51) 3.9  (3.4) 3.6  (1.9) 3.2  (2.6) 0.224 
Oligofructose intakes, g/d, median (IQR)        
 All Crohn’s disease 3.4  (1.7) 3.2  (2.0) 2.9  (2.1) 0.281 
 Active Crohn’s  2.8  (2.1) 2.5  (1.6) 2.9  (1.9) 0.910 
 Inactive Crohn’s  3.6  (3.4) 3.5  (1.8) 2.9  (2.7) 0.215 
        
Disease Behaviour Non stricturing, 
non-penetrating  
Stricturing  Penetrating  P value* 
Total fructan intakes, g/d, median (IQR)        
 All Crohn’s disease (n=107, 58, 32) 3.1  (2.3) 3.3  (2.7) 2.9  (1.3) 0.597 
 Active Crohn’s (n=50, 29, 19) 2.5  (1.7) 3.2  (2.0) 2.9  (1.7) 0.508 
 Inactive Crohn’s (n=57, 29, 13) 3.6  (1.9) 3.6  (3.3) 3.1  (1.5) 0.832 
Oligofructose intakes, g/d, median (IQR)        
 All Crohn’s disease 3.1  (2.1) 3.2  (2.6) 2.9  (1.3) 0.498 
 Active Crohn’s  2.3  (1.8) 3.0  (2.0) 2.8  (1.7) 0.424 
 Inactive Crohn’s  3.4  (1.8) 3.6  (3.0) 3.1  (1.5) 0.832 
*
 P values are the result of a Kruskal Wallis Test 557 
 558 
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Table 5 Spearman’s rho correlation between Harvey Bradshaw Index total score, and 559 
component scores, and intakes of total fructans and oligofructose 560 
*
 Spearman’s rho correlation coefficient (ρ) 561 
†
 Correlation is significant at the 0.05 level (2-tailed) 562 
 563 
 All Crohn’s  
(n=197) 
Active Crohn’s  
(n=98) 
Inactive Crohn’s 
(n=99) 
 
ρ
*
 P value ρ* P value ρ* P value 
Total fructan intake       
HBI Total Score -0.131 0.066 -0.081 0.429 0.182 0.071 
 Wellbeing 
-0.154† 0.030 -0.115 0.260 0.082 0.417 
 Abdominal Pain 
-0.164† 0.021 -0.216† 0.032 0.170 0.093 
 Liquid stools -0.127 0.075 -0.001 0.990 0.141 0.163 
 Abdominal Mass -0.040 0.573 0.034 0.740 - - 
 Complications -0.014 0.844 0.162 0.112 0.027 0.787 
Oligofructose intake       
HBI Total Score -0.128 0.073 -0.084 0.413 0.169 0.095 
 Wellbeing 
-0.156† 0.028 -0.114 0.262 0.051 0.615 
 Abdominal Pain -0.157† 0.027 -0.208† 0.040 0.152 0.132 
 Liquid stools -0.121 0.089 -0.004 0.970 0.146 0.149 
 Abdominal Mass -0.033 0.648 0.038 0.712 - - 
 Complications -0.010 0.891 0.158 0.120 0.028 0.785 
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